Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial
Okugawa et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2023.106922
https://c19early.org/okugawanf.html